Member Info for dallo

JTT
Surely we don't have to point out to a very high calibre Board of Directors the blatantly obvious.
The upcoming IPO of Akili will add another cashable amount to the Puretech arsenal so they should set a medium term objective of getting the SP back up to £3
by accelerating the buybacks and hopefully pushing the SP higher still with the Akili news and maybe Vedanta together with all the other milestone newsflow this year.

As someone who has been here for over 6 years IMMU continues to keep investors on edge as we fret about the upcoming FDA decision .
Surely after the successful PK tests the decision should be straightforward but this is IMMU and cliffhangers are standard.
But now we have the Alora Pharma Group sponsoring the application so maybe Alora/ Avion committing c $25m to the Phase 3 trial and chucking in c£1.3m in the recent placing at 11p maybe our luck may be about to change.
Nail biting as ever.
ATB

At an average daily buyback volume of 40/50k it will take Puretech/ Jefferies nearly 500 business days to complete the buyback programme.
This a joke and now is the time to hoover up the shares when the SP is near multi year lows.
So what if the buybacks drive the SP to 250p plus ...it will still be 40% below its high of a year or so ago.
Get the finger out!!!!

According to the Investors Chronicle article of a week or so ago there has been a significant short interest taken in Puretech in recent months in line with the general collapse in Pharma shares but the article said this shorting is not justified given the strength of the company.
This article was before the announcement of the $50m buyback and this firepower allied to short closing could whiplash the SP much higher in the coming weeks imho.
Also it appears Jefferies is beginning to crank up the buying as obviously it takes a few days to organise an orderly buyback programme.

False alarm...go back to sleep everyone!
Doh!

A sudden bounce out of nowhere
Maybe just maybe news is imminent.

Just a thought...maybe Jefferies has to wait for the Nasdaq market to open before buying as otherwise you are creating an anomaly between the two markets which may breach regulatory rules.

If they are clever they will be patient as it appears that the Nasdaq still has a way to go before reaching the bottom of this savage correction ( down c30% from high late last year).
A further drop of 10% in the Nasdaq is possible which would represent one of the worst corrections in modern times.
I feel we are close to the end of this miserable bear market with perhaps a final capitulation to come.
Puretech can maximise its buy backs to the eventual benefit of shareholders if it plays the markets correctly imho.
Still painful to watch nonetheless.

Here's Hoping
I have reported your post in relation to your totally libelous comments about that the word fraud is appearing a little more about this company.
This is despicable behavior from a new poster who mysteriously appeared in the past few days.
I am sickened by some of the postings here and will never post again.

Nota
Excellent summary and it accords with my views.
The FDA decision is obviously critical to any investment case and if positive will underpin IMMU for the duration of the Phase 3 trial and with the other peptide therapies maybe giving a further boost along the way.
A successful FDA decision will certainly spike interest in IMMU and I suspect TM would welcome an exit at some stage.
Guessing at what share price level any takeout would occur at is pure speculation at this stage.
ATB

Jtt
With the SP in the bargain basement the share buyout will be even more effective by acquiring a large number of shares for Treasury.
The sooner the buyout starts the better

Down again to multi year lows...Puretech better get its chequebook out quickly....utterly amazing share price performance and inexplicable in my view.

Doesn't change my investment thesis..correction

Nolupus
I hope you weren't referring to my post where I said IF the FDA approves the Phase 3 trial investors have a timeliness decision to make.
I also said you pays your money and take your chances depending on whether you are a short-term or long term investor.
Any idiot knows Phase 3 trials can take up to 2 years to complete but that change my investment thesis.

Draye
There are going to be 2 investment decisions to be made if the FDA approves the Phase 3 trials for Lupuzor.
One is short term...Alora/Avion will pay for the full amount of the trials and if successful obtain full US rights to marketing Lupuzor with royalties and front up payments to IMMU with IMMU free do a similar deal with another Pharma for the rest of the world.
To have a drug in Phase 3 trials is highly valued by the Pharma industry so you could expect a major jump in the IMMU share price following FDA approval.
So short-term investors may want to get out if approval is granted while long-term investors may stay for the result of the trials.
The other peptide suite could be pushed on with a big Pharma backing with IMMU getting royalties etc if successful.
Either way the mega catalyst for the SP is the FDA decision..you bet your money and take your chances.
I personally think the FDA will grant approval to a US company like Alora/Avion who are willing to invest $25 m in a trial but please DYOR.
ATB

Puretech can buyback around 22m shares at the current SP of 184p which given the daily liquidity/volumes of around 100,000 or so is going to really support the SP and the SP lows of 165p are now gone...onwards and upwards.

Pawn
At the outrageous low SP buybacks are the perfect way to drive the SP higher given the relative illiquidity
in the share.
More returns to shareholders following Akili ( and Vedanta) listings and today is just the start in correcting the blatant SP undervaluation.

Nolupus
In fairness Franklin, Lisa ,the non executive Director plus other staff invested as well not to mention Alora ( Art Deas) chucking over £1.1m in the placing.
If IMMU can do a similar deal on the other peptide suite of drugs with a large Pharma as done with Alora
on Lupuzor then the cash needs of IMMU may not be significant.
All to play for here and the FDA decision on the Lupuzor Phase 3 trial could be transform the SP and allow an exit for some who don't wish to await the end results.
Still hold 2.5 m at average of 14p...stubborn is my middle name!

It looks like 5G offloaded a minimum of 1.2m shares over the past 5 months following its declaration of a holding of c6.5% in December.
Given the crash in tech stocks during this period and the illiquidity of ENET shares that has been enough to hammer the SP.
What is its motivation for doing such damage I wonder.
A supportive investor....I very much doubt it.
It is the responsibility of the company to maintain an orderly market in its shares and work in the interests of its shareholders.
It must now act accordingly imho.
Dyor

Skid
Fully agree .
SP collapse totally disproportionate to the number of shares sold....illiquidity can hammer a share on the downside as we are seeing today with no buyers at all.
A perfect hurricane for the poor ENET SP.
We will have to ride out the storm as selling now is madness imho.
ATB